DelveInsight Releases Report on Complement 3 Glomerulopathy Drug Pipeline

Market research firm DelveInsight has released its latest report, “Complement 3 Glomerulopathy - Pipeline Insight, 2026.” The report provides a comprehensive analysis of the current drug development landscape and future prospects for Complement 3 Glomerulopathy (C3G), a rare kidney disease.

C3G arises from genetic or acquired issues within the body's complement system, which aids in fighting infections. The condition presents in two forms: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). The report covers over three companies and more than three drug candidates currently in clinical or preclinical development stages.

The analysis specifically highlights drugs under development by Novartis Pharmaceuticals. Avacopan, an orally administered C5a receptor inhibitor, is in Phase II trials for C3G treatment. Additionally, Novartis is developing Iptacopan, an oral inhibitor of factor B in the alternative complement pathway, which holds potential as a first-in-class targeted therapy to delay progression to dialysis for C3G patients.

The report assesses the pipeline based on product type, stage, route of administration, and molecule type. It also details inactive pipeline products and examines collaborations, licensing deals, and funding. The analysis covers more than three key global players who have advanced their drug candidates, particularly those in Phase II development.